Exploratory comparative pharmacokinetic study of a fixed-dose combination of telmisartan/amlodipine/chlorthalidone: half-dose (20/2.5/6.25 mg) versus conventional dose (40/5/12.5 mg)

Read full text Summarise with VIRAT
Authors: Kyungrin Chang, Heejae Won, Taewon Lee, Soonkeun Kwon, Seung Hwan Lee, Joo‐Youn Cho, Kyung‐Sang Yu
Cited by: 0
References: 25

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Low-dose combination therapies are recommended when monotherapy fails to control hypertension.This exploratory study aimed to compare the pharmacokinetics (PK) of 2 fixeddose combinations (FDCs) of telmisartan, amlodipine, and chlorthalidone: half-dose test FDC (20/2.5/6.25 mg) and a conventional-dose reference FDC (40/5/12.5mg).A randomized, open-label, single-dose, parallel-group study was conducted in healthy participants.Each participant received a single oral dose of either the test or reference FDC.Serial blood samples for telmisartan, amlodipine, and chlorthalidone were collected up to 72 hours post-dose, and PK parameters were calculated using noncompartmental analysis.The mean maximum plasma concentrations (C max ) of telmisartan, amlodipine, and chlorthalidone were 41.34 and 155.75 μg/L, 1.74 and 4.42 μg/L, and 39.36 and 104.86 μg/L for the test and reference FDCs, respectively.The mean area under the concentration-time curves to the last measurable time point (AUC last ) were 659.93 and 1673.51h•μg/L for telmisartan, 57.98 and 128.75 h•μg/L for amlodipine, and 831.73 and 1826.86 h•μg/L for chlorthalidone.The test FDC demonstrated systemic exposure levels ranging from 0.27-to 0.39-fold for telmisartan, 0.39-to 0.44-fold for amlodipine, and 0.38-to 0.46-fold for chlorthalidone, compared to the reference FDC.In conclusion, the PK profiles of the half-dose test FDC were consistent with the known characteristics of the individual components.These provide the first PK data for this half-dose test FDC and may support its potential as an alternative treatment option for hypertension.However, as this was an exploratory study, the results should be interpreted with caution.

Fields of Study & Subjects

Blood Pressure and Hypertension Studies Pharmacogenetics and Drug Metabolism Renin-Angiotensin System Studies

Publication details

Journal / source
Translational and Clinical Pharmacology
Volume
34
Issue
1
Pages
45–45
Publication date
1 March 2026
Language
EN